70 likes | 91 Views
Learn about the growth and impact of CU's technology transfer program, creating companies, securing patents, fostering innovation, and driving economic growth. Explore future challenges and opportunities in this comprehensive update.
E N D
2008 Update on Technology Transfer at the University of Colorado David N. Allen Associate VP for Technology Transfer University of Colorado 303 735 1688 david.allen@cu.edu
FY 2007-08 Review • CU technology transfer continues to advance and provide benefits to the University, the Colorado economy and society. • Highlights of the year – • Growth in exclusive license and option activity • Eleven new companies created based on CU intellectual property and continued success of companies in the portfolio • Increasing leverage of State bioscience funding program • Decrease in non-exclusive licenses • First year of decreased revenues
CU Technology Transfer Today Fiscal Year 03-4 04-5 05-6 06-7 07-08 Invention disclosures 147 177 198 254 237 Patent apps filed 100 139 125 177 188 Options and licenses 47 59 57 75 58 Exclusive option/licenses 19 22 36 38 45 Revenue in $MM* 5.8 21.7 20.6 24.0 6.1 Start-up companies 9 9 10 10 11 * does not include revenue derived from legal settlements which in FY2003-4 amounted to $28.1M, in FY2004-5 $6.7M, in FY 2005-6 $.7M and $.5M in 2006-7
Companies Created Based on CU IP • Eleven companies (start-ups) created from CU IP last FY • 83 start-ups in the past 15 years; all but twelve remain operational • 67 start-ups have Colorado operations • Fourteen start-ups have received CU TTO Proof-of-Concept investments • Fifteen IPOs and acquisition events have occurred within the start-up portfolio
The Maturing Intellectual Property and Licensing Portfolio • 269 active patents • 267 active patent applications • 113 active exclusive licenses and 20 options to exclusive licenses • 190 active nonexclusive licenses • 44 therapeutics, 32 diagnostic tests and 37 medical devices in preclinical development
Social, Clinical and Economic Impacts of CU Technology Transfer • Three FDA approved drugs being sold • Three drugs in Phase III clinical trials • 11 drugs in Phase II clinical trials • Six drugs in Phase I clinical trials • Companies created from CU IP secured $116M in investment capital in 2006 • 30 total products being sold based on CU IP
Continuing the Momentum and Facing New Challenges and Opportunities • Reliable flow of IP and license transactions based on active research investigators, consistent IP practices, staff development, outreach, and leveraging • Challenges… • Retaining CU’s team of quality technology transfer professionals • Two licensing professionals promoted to Senior Licensing positions • Major patent expiration and end of monetization agreement resulted in the first of three years of projected revenue downturn • New License Income in FY 07-08 = $.9M, higher than projected • New opportunities… • State of Colorado Bioscience Development grant for five years • Colorado Renewable Energy initiatives